XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Reconciliation of Revenue from Segments to Consolidated The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
OmniAb business revenue
  Royalties$582 $— $984 $— 
  Contract6,285 5,140 22,353 19,520 
Total OmniAb business revenue
6,867 5,140 23,337 19,520 
Ligand core business revenue
  Royalties19,255 15,648 50,507 $31,376 
  Captisol - Core 3,582 5,374 13,133 16,310 
  Captisol - COVID32,367 29,719 64,483 112,565 
  Contract4,017 8,954 17,740 24,889 
 Total Ligand core business revenue59,221 59,695 145,863 185,140 
     Total revenue$66,088 $64,835 $169,200 $204,660 
Segment operating income (loss)
OmniAb business
$(11,721)$(9,177)$(26,905)$(21,587)
Ligand core business22,022 32,620 49,050 112,601 
Total segment operating income10,301 23,443 22,145 91,014 
Unallocated corporate items
Shared-based compensation6,462 5,811 17,255 16,429 
Other corporate expenses3,203 1,926 14,029 8,424 
  Total unallocated corporate items9,665 7,737 31,284 24,853 
Income (loss) from operations$636 $15,706 $(9,139)$66,161